Literature DB >> 20674334

Interconversion of three measures of performance status: an empirical analysis.

Clement Ma1, Shazeen Bandukwala, Debika Burman, John Bryson, Dori Seccareccia, Subrata Banerjee, Jeff Myers, Gary Rodin, Deborah Dudgeon, Camilla Zimmermann.   

Abstract

PURPOSE: To construct empirically a conversion table to convert performance status scores among the Eastern Cooperative Oncology Group (ECOG), Karnofsky Performance Status (KPS) and Palliative Performance Scale (PPS) measures, using a large sample of patients with advanced cancer.
METHODS: Seven physicians completed assessments on 1385 consecutive patients attending an oncology palliative care clinic, or admitted to an acute cancer palliative care unit. The three measures were distributed as a questionnaire package; the order in which they were presented was randomly assigned for each week. Scales were compared using the hit rate and the weighted kappa coefficient (κ(w)). The KPS and PPS were compared directly; for comparisons of either scale with the ECOG, all 70 possible categorisations of KPS and PPS were computed. An 'ideal' categorisation was selected based on maximisation of both statistical methods.
RESULTS: The KPS and PPS matched in 1209 out of 1385 assessments (hit rate 87%; κ(w) 0.97). For both the KPS and the PPS, the categorisation of 100 (ECOG 0), 80-90 (1), 60-70 (2), 40-50 (3), 10-30 (4) had the highest hit rate (75%), and the second highest κ(w) (0.84, p<0.0001). One other combination had a slightly higher κ(w) (0.85 for both KPS and PPS), but a lower hit rate (73% for KPS, 72% for PPS).
CONCLUSIONS: We have derived empirically a conversion scale among the ECOG, KPS and PPS scales. The proposed scale provides a means of translating amongst these measures, which may improve accuracy of communication about performance status amongst oncology clinicians and researchers.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20674334     DOI: 10.1016/j.ejca.2010.06.126

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  50 in total

1.  Further evaluation of the EORTC QLQ-C30 psychometric properties in a large Brazilian cancer patient cohort as a function of their educational status.

Authors:  Carlos Eduardo Paiva; Estela Cristina Carneseca; Eliane Marçon Barroso; Mayara Goulart de Camargos; Ana Camila Callado Alfano; Fernanda Capella Rugno; Bianca Sakamoto Ribeiro Paiva
Journal:  Support Care Cancer       Date:  2014-03-21       Impact factor: 3.603

2.  Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response.

Authors:  Barry J A Laird; Marie Fallon; Marianne J Hjermstad; Sharon Tuck; Stein Kaasa; Pål Klepstad; Donald C McMillan
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

3.  On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points?

Authors:  M E Hamaker; R Stauder; B C van Munster
Journal:  Ann Oncol       Date:  2014-01-23       Impact factor: 32.976

4.  A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study.

Authors:  Brice Chanez; François Bertucci; Marine Gilabert; Anne Madroszyk; Frédérique Rousseau; Delphine Perrot; Patrice Viens; Jean-Luc Raoul
Journal:  Support Care Cancer       Date:  2017-03-28       Impact factor: 3.603

Review 5.  Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Davendra P S Sohal; Pamela B Mangu; Alok A Khorana; Manish A Shah; Philip A Philip; Eileen M O'Reilly; Hope E Uronis; Ramesh K Ramanathan; Christopher H Crane; Anitra Engebretson; Joseph T Ruggiero; Mehmet S Copur; Michelle Lau; Susan Urba; Daniel Laheru
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

Review 6.  Treating glioblastoma patients with poor performance status: where do we go from here?

Authors:  Jaime Gállego Pérez-Larraya; François Ducray
Journal:  CNS Oncol       Date:  2014-05

7.  Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry.

Authors:  Marije E Hamaker; Reinhard Stauder; Barbara C van Munster
Journal:  Oncologist       Date:  2014-08-28

8.  Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Authors:  Josep Tabernero; E Gabriela Chiorean; Jeffrey R Infante; Sunil R Hingorani; Vinod Ganju; Colin Weekes; Werner Scheithauer; Ramesh K Ramanathan; David Goldstein; Darryl N Penenberg; Alfredo Romano; Stefano Ferrara; Daniel D Von Hoff
Journal:  Oncologist       Date:  2015-01-12

9.  Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.

Authors:  Sonali Rudra; Amol K Narang; Timothy M Pawlik; Hao Wang; Elizabeth M Jaffee; Lei Zheng; Dung T Le; David Cosgrove; Ralph H Hruban; Elliot K Fishman; Richard Tuli; Daniel A Laheru; Christopher L Wolfgang; Luis A Diaz; Joseph M Herman
Journal:  Pract Radiat Oncol       Date:  2012

10.  Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.

Authors:  Filipa Lynce; Matthew J Blackburn; Ling Cai; Heping Wang; Larry Rubinstein; Pamela Harris; Claudine Isaacs; Paula R Pohlmann
Journal:  Breast Cancer Res Treat       Date:  2017-11-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.